A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Fasinumab (Primary) ; Naproxen
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT OA1
- Sponsors Regeneron Pharmaceuticals
- 27 Apr 2018 Planned End Date changed from 1 Oct 2020 to 30 Nov 2020.
- 27 Apr 2018 Planned primary completion date changed from 1 Mar 2019 to 22 Apr 2019.
- 25 Aug 2017 Status changed from not yet recruiting to recruiting.